$17.60
-0.15-0.85%
After Hours: 9:00 AM EDT
15 minutes delayed
Comments
Loading...
ACADIA Pharmaceuticals
ACADNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock, Analyst Ratings, Price Targets, Forecasts
ACADIA Pharmaceuticals Inc has a consensus price target of $28.57 based on the ratings of 23 analysts. The high is $42 issued by Cantor Fitzgerald on August 22, 2023. The low is $19 issued by Oppenheimer on May 6, 2024. The 3 most-recent analyst ratings were released by Morgan Stanley, BMO Capital, and RBC Capital on July 12, 2024, June 27, 2024, and June 25, 2024, respectively. With an average price target of $29.33 between Morgan Stanley, BMO Capital, and RBC Capital, there's an implied 61.97% upside for ACADIA Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
BMO Capital
RBC Capital
B of A Securities
Needham
1calculated from analyst ratings
Analyst Ratings for ACADIA Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/12/2024 | Buy Now | 54.61% | Morgan Stanley | Jeffrey Hung | $30 → $28 | Maintains | Overweight | Get Alert |
| 06/27/2024 | Buy Now | 71.18% | BMO Capital | Keith Tapper | → $31 | Initiates | → Outperform | Get Alert |
| 06/25/2024 | Buy Now | 60.13% | RBC Capital | Gregory Renza | $29 → $29 | Reiterates | Outperform → Outperform | Get Alert |
| 05/10/2024 | Buy Now | 21.48% | B of A Securities | Tazeen Ahmad | $26 → $22 | Maintains | Neutral | Get Alert |
| 05/09/2024 | Buy Now | 65.65% | Needham | Ami Fadia | → $30 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 104.31% | Cantor Fitzgerald | Charles Duncan | → $37 | Reiterates | Overweight → Overweight | Get Alert |
| 05/09/2024 | Buy Now | 49.09% | HC Wainwright & Co. | Andrew Fein | $33 → $27 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 65.65% | Citigroup | David Hoang | $30.19 → $30 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 15.96% | Stifel | Paul Matteis | $26 → $21 | Maintains | Hold | Get Alert |
| 05/09/2024 | Buy Now | 15.96% | Mizuho | Uy Ear | $25 → $21 | Maintains | Neutral | Get Alert |
| 05/09/2024 | Buy Now | 54.61% | Baird | Joel Beatty | $31 → $28 | Maintains | Outperform | Get Alert |
| 05/06/2024 | Buy Now | 4.91% | Oppenheimer | Jay Olson | $19 → $19 | Maintains | Perform | Get Alert |
| 04/30/2024 | Buy Now | 104.31% | Cantor Fitzgerald | Charles Duncan | → $37 | Reiterates | Overweight → Overweight | Get Alert |
| 04/10/2024 | Buy Now | 104.31% | Cantor Fitzgerald | Charles Duncan | → $37 | Reiterates | Overweight → Overweight | Get Alert |
| 04/09/2024 | Buy Now | 76.7% | Needham | Ami Fadia | → $32 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2024 | Buy Now | 38.05% | JP Morgan | Tessa Romero | $29 → $25 | Maintains | Overweight | Get Alert |
| 03/13/2024 | Buy Now | 65.65% | Morgan Stanley | Jeffrey Hung | $40 → $30 | Maintains | Overweight | Get Alert |
| 03/12/2024 | Buy Now | 66.7% | Citigroup | David Hoang | $38 → $30.19 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 65.65% | RBC Capital | Gregory Renza | $35 → $30 | Maintains | Outperform | Get Alert |
| 03/12/2024 | Buy Now | 38.05% | Mizuho | Uy Ear | $39 → $25 | Downgrade | Buy → Neutral | Get Alert |
| 03/12/2024 | Buy Now | 115.35% | JMP Securities | Jason Butler | $44 → $39 | Maintains | Outperform | Get Alert |
| 03/12/2024 | Buy Now | 104.31% | Cantor Fitzgerald | Charles Duncan | $42 → $37 | Maintains | Overweight | Get Alert |
| 03/12/2024 | Buy Now | 71.18% | Baird | Joel Beatty | $40 → $31 | Maintains | Outperform | Get Alert |
| 03/12/2024 | Buy Now | 4.91% | Oppenheimer | Jay Olson | $25 → $19 | Maintains | Perform | Get Alert |
| 03/12/2024 | Buy Now | 65.65% | B of A Securities | Tazeen Ahmad | $33 → $30 | Maintains | Neutral | Get Alert |
| 03/12/2024 | Buy Now | 82.22% | Canaccord Genuity | Sumant Kulkarni | $40 → $33 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 82.22% | HC Wainwright & Co. | Andrew Fein | → $33 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2024 | Buy Now | 76.7% | Needham | Ami Fadia | $36 → $32 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | 60.13% | JP Morgan | Tessa Romero | $32 → $29 | Maintains | Overweight | Get Alert |
| 02/28/2024 | Buy Now | 82.22% | HC Wainwright & Co. | Andrew Fein | → $33 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 131.92% | Cantor Fitzgerald | Charles Duncan | → $42 | Reiterates | Overweight → Overweight | Get Alert |
| 02/28/2024 | Buy Now | 93.26% | RBC Capital | Gregory Renza | $36 → $35 | Maintains | Outperform | Get Alert |
| 02/28/2024 | Buy Now | 115.35% | Mizuho | Uy Ear | $40 → $39 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 98.79% | Needham | Ami Fadia | $37 → $36 | Maintains | Buy | Get Alert |
| 02/07/2024 | Buy Now | 131.92% | JMP Securities | Jason Butler | → $42 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/05/2024 | Buy Now | 38.05% | Oppenheimer | Jay Olson | → $25 | Reiterates | Perform → Perform | Get Alert |
| 02/02/2024 | Buy Now | 131.92% | Cantor Fitzgerald | Charles Duncan | → $42 | Reiterates | Overweight → Overweight | Get Alert |
| 01/30/2024 | Buy Now | 120.87% | Baird | Joel Beatty | → $40 | Initiates | → Outperform | Get Alert |
| 01/24/2024 | Buy Now | 104.31% | Needham | Joseph Stringer | → $37 | Upgrade | Hold → Buy | Get Alert |
| 12/29/2023 | Buy Now | 120.87% | Mizuho | Uy Ear | $35 → $40 | Maintains | Buy | Get Alert |
| 12/19/2023 | Buy Now | 120.87% | Morgan Stanley | Jeffrey Hung | $31 → $40 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/18/2023 | Buy Now | 49.09% | Stifel | Paul Matteis | $25 → $27 | Maintains | Hold | Get Alert |
| 12/14/2023 | Buy Now | 131.92% | Cantor Fitzgerald | Charles Duncan | → $42 | Reiterates | Overweight → Overweight | Get Alert |
| 12/14/2023 | Buy Now | 38.05% | Deutsche Bank | Neena Bitritto-Garg | → $25 | Downgrade | Buy → Hold | Get Alert |
| 12/13/2023 | Buy Now | 109.83% | Citigroup | David Hoang | → $38 | Initiates | → Buy | Get Alert |
| 12/12/2023 | Buy Now | 38.05% | Deutsche Bank | Neena Bitritto-Garg | → $25 | Initiates | → Buy | Get Alert |
| 11/06/2023 | Buy Now | 120.87% | Canaccord Genuity | Sumant Kulkarni | $38 → $40 | Maintains | Buy | Get Alert |
| 11/06/2023 | Buy Now | 93.26% | Mizuho | Uy Ear | $20 → $35 | Upgrade | Neutral → Buy | Get Alert |
| 11/03/2023 | Buy Now | 131.92% | JMP Securities | Jason Butler | $39 → $42 | Maintains | Market Outperform | Get Alert |
| 11/03/2023 | Buy Now | 82.22% | RBC Capital | Gregory Renza | $32 → $33 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | 71.18% | Morgan Stanley | Jeffrey Hung | $30 → $31 | Maintains | Equal-Weight | Get Alert |
| 10/17/2023 | Buy Now | 82.22% | UBS | Ashwani Verma | → $33 | Initiates | → Buy | Get Alert |
| 10/10/2023 | Buy Now | 76.7% | JP Morgan | Tessa Romero | $29 → $32 | Upgrade | Neutral → Overweight | Get Alert |
| 08/22/2023 | Buy Now | 131.92% | Cantor Fitzgerald | Sarah James | → $42 | Reiterates | Overweight → Overweight | Get Alert |
| 08/07/2023 | Buy Now | 60.13% | JP Morgan | Julio Romero | $28 → $29 | Maintains | Neutral | Get Alert |
| 08/03/2023 | Buy Now | 109.83% | Canaccord Genuity | Sumant Kulkarni | $39 → $38 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | 65.65% | Morgan Stanley | Jeffrey Hung | $30 → $30 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/03/2023 | Buy Now | 38.05% | Oppenheimer | Jay Olson | → $25 | Reiterates | Perform → Perform | Get Alert |
| 08/03/2023 | Buy Now | 82.22% | HC Wainwright & Co. | Andrew Fein | → $33 | Reiterates | Buy → Buy | Get Alert |
| 07/28/2023 | Buy Now | 38.05% | Oppenheimer | Jay Olson | $23 → $25 | Maintains | Perform | Get Alert |
| 07/17/2023 | Buy Now | 115.35% | Canaccord Genuity | Sumant Kulkarni | $28 → $39 | Maintains | Buy | Get Alert |
| 07/17/2023 | Buy Now | 131.92% | Cantor Fitzgerald | Sarah James | $36 → $42 | Maintains | Overweight | Get Alert |
| 07/14/2023 | Buy Now | 82.22% | RBC Capital | Gregory Renza | $28 → $33 | Maintains | Outperform | Get Alert |
| 07/14/2023 | Buy Now | 49.09% | Citigroup | Neena Bitritto-Garg | $21.6 → $27 | Maintains | Neutral | Get Alert |
| 07/14/2023 | Buy Now | 65.65% | Morgan Stanley | Jeffrey Hung | $21 → $30 | Maintains | Equal-Weight | Get Alert |
| 07/14/2023 | Buy Now | 115.35% | JMP Securities | Jason Butler | $31 → $39 | Maintains | Market Outperform | Get Alert |
| 07/14/2023 | Buy Now | 27% | Oppenheimer | Jay Olson | $20 → $23 | Maintains | Perform | Get Alert |
| 07/14/2023 | Buy Now | 82.22% | HC Wainwright & Co. | Andrew Fein | $28 → $33 | Maintains | Buy | Get Alert |
| 07/11/2023 | Buy Now | 15.96% | Morgan Stanley | Jeffrey Hung | $20 → $21 | Maintains | Equal-Weight | Get Alert |
| 06/14/2023 | Buy Now | 71.18% | JMP Securities | Jason Butler | $23 → $31 | Maintains | Market Outperform | Get Alert |
| 06/14/2023 | Buy Now | 10.44% | Mizuho | Uy Ear | → $20 | Reiterates | Neutral → Neutral | Get Alert |
| 06/14/2023 | Buy Now | 54.61% | HC Wainwright & Co. | Andrew Fein | → $28 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2023 | Buy Now | 43.57% | B of A Securities | Tazeen Ahmad | $23 → $26 | Maintains | Neutral | Get Alert |
| 05/09/2023 | Buy Now | 82.22% | Cantor Fitzgerald | Sarah James | → $33 | Reiterates | → Overweight | Get Alert |
| 05/09/2023 | Buy Now | 49.09% | RBC Capital | Gregory Renza | → $27 | Reiterates | → Outperform | Get Alert |
| 05/09/2023 | Buy Now | 27% | JMP Securities | Jason Butler | $22 → $23 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | 54.61% | HC Wainwright & Co. | Andrew Fein | → $28 | Reiterates | → Buy | Get Alert |
| 05/09/2023 | Buy Now | 19.27% | Citigroup | Neena Bitritto-Garg | $21 → $21.6 | Maintains | Neutral | Get Alert |
| 04/14/2023 | Buy Now | 10.44% | Mizuho | Uy Ear | → $20 | Reiterates | → Neutral | Get Alert |
| 03/20/2023 | Buy Now | 15.96% | JP Morgan | Julio Romero | $19 → $21 | Maintains | Neutral | Get Alert |
| 03/14/2023 | Buy Now | 27% | B of A Securities | Tazeen Ahmad | → $23 | Maintains | Neutral | Get Alert |
| 03/14/2023 | Buy Now | 10.44% | Morgan Stanley | Jeffrey Hung | $19 → $20 | Maintains | Equal-Weight | Get Alert |
| 03/14/2023 | Buy Now | 49.09% | RBC Capital | Gregory Renza | → $27 | Reiterates | → Outperform | Get Alert |
| 03/14/2023 | Buy Now | 43.57% | Canaccord Genuity | Sumant Kulkarni | $24 → $26 | Maintains | Buy | Get Alert |
| 03/14/2023 | Buy Now | 82.22% | Cantor Fitzgerald | Charles Duncan | $28 → $33 | Maintains | Overweight | Get Alert |
| 03/14/2023 | Buy Now | 15.96% | Citigroup | Neena Bitritto-Garg | $19.4 → $21 | Maintains | Neutral | Get Alert |
| 03/14/2023 | Buy Now | 54.61% | HC Wainwright & Co. | Andrew Fein | $25 → $28 | Maintains | Buy | Get Alert |
| 03/13/2023 | Buy Now | 4.91% | Mizuho | Uy Ear | → $19 | Reiterates | → Neutral | Get Alert |
| 03/01/2023 | Buy Now | 10.44% | Oppenheimer | Jay Olson | $17 → $20 | Maintains | Perform | Get Alert |
| 02/28/2023 | Buy Now | 38.05% | HC Wainwright & Co. | Andrew Fein | → $25 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 21.48% | JMP Securities | Jason West | $24 → $22 | Maintains | Market Perform | Get Alert |
| 02/28/2023 | Buy Now | 7.12% | Citigroup | Neena Bitritto-Garg | $19 → $19.4 | Maintains | Neutral | Get Alert |
| 02/28/2023 | Buy Now | 49.09% | RBC Capital | Gregory Renza | $19 → $27 | Maintains | Outperform | Get Alert |
| 02/28/2023 | Buy Now | 4.91% | Morgan Stanley | Jeffrey Hung | $18 → $19 | Maintains | Equal-Weight | Get Alert |
| 02/28/2023 | Buy Now | 4.91% | Mizuho | Uy Ear | $15 → $19 | Maintains | Neutral | Get Alert |
| 02/15/2023 | Buy Now | -6.13% | Oppenheimer | Jay Olson | $16 → $17 | Maintains | Perform | Get Alert |
| 01/31/2023 | Buy Now | 4.91% | Citigroup | Neena Bitritto-Garg | $17 → $19 | Maintains | Neutral | Get Alert |
| 01/03/2023 | Buy Now | 21.48% | Guggenheim | Yatin Suneja | → $22 | Upgrade | Neutral → Buy | Get Alert |
| 12/21/2022 | Buy Now | -17.17% | Mizuho | Uy Ear | $17 → $15 | Maintains | Neutral | Get Alert |
| 11/14/2022 | Buy Now | -6.13% | JP Morgan | Tessa Romero | $19 → $17 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for ACADIA Pharmaceuticals (ACAD) stock?
The latest price target for ACADIA Pharmaceuticals (NASDAQ:ACAD) was reported by Morgan Stanley on July 12, 2024. The analyst firm set a price target for $28.00 expecting ACAD to rise to within 12 months (a possible 54.61% upside). 60 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ACADIA Pharmaceuticals (ACAD)?
The latest analyst rating for ACADIA Pharmaceuticals (NASDAQ:ACAD) was provided by Morgan Stanley, and ACADIA Pharmaceuticals maintained their overweight rating.
When was the last upgrade for ACADIA Pharmaceuticals (ACAD)?
The last upgrade for ACADIA Pharmaceuticals Inc happened on January 24, 2024 when Needham raised their price target to $37. Needham previously had a hold for ACADIA Pharmaceuticals Inc.
When was the last downgrade for ACADIA Pharmaceuticals (ACAD)?
The last downgrade for ACADIA Pharmaceuticals Inc happened on March 12, 2024 when Mizuho changed their price target from $39 to $25 for ACADIA Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for ACADIA Pharmaceuticals (ACAD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ACADIA Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ACADIA Pharmaceuticals was filed on July 12, 2024 so you should expect the next rating to be made available sometime around July 12, 2025.
Is the Analyst Rating ACADIA Pharmaceuticals (ACAD) correct?
While ratings are subjective and will change, the latest ACADIA Pharmaceuticals (ACAD) rating was a maintained with a price target of $30.00 to $28.00. The current price ACADIA Pharmaceuticals (ACAD) is trading at is $18.11, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.